TECH Bio-Techne Corporation Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

TECH [NASD]

Bio-Techne Corporation

Healthcare | Biotechnology | USA

statements

Index	-	P/E	57.92	EPS (ttm)	4.74	Insider Own	0.40%	Shs Outstand	38.30M	Perf Week	0.11%
Market Cap	10.68B	Forward P/E	52.03	EPS next Y	5.27	Insider Trans	-38.58%	Shs Float	38.03M	Perf Month	7.84%
Income	186.90M	PEG	9.65	EPS next Q	0.75	Inst Own	97.60%	Short Float	1.55%	Perf Quarter	36.14%
Sales	754.50M	P/S	14.15	EPS this Y	1.10%	Inst Trans	0.03%	Short Ratio	2.12	Perf Half Y	25.91%
Book/sh	33.71	P/B	8.14	EPS next Y	22.46%	ROA	9.60%	Target Price	253.38	Perf Year	30.45%
Cash/sh	6.71	P/C	40.89	EPS next 5Y	6.00%	ROE	15.10%	52W Range	155.17 - 282.52	Perf YTD	24.96%
Dividend	1.28	P/FCF	87.87	EPS past 5Y	-3.80%	ROI	6.90%	52W High	-2.91%	Beta	1.13
Dividend %	0.47%	Quick Ratio	3.70	Sales past 5Y	14.80%	Gross Margin	66.00%	52W Low	76.77%	ATR	9.21
Employees	2250	Current Ratio	4.70	Sales Q/Q	5.30%	Oper. Margin	21.40%	RSI (14)	57.40	Volatility	3.64% 3.30%
Optionable	Yes	Debt/Eq	0.33	EPS Q/Q	-19.60%	Profit Margin	24.80%	Rel Volume	0.60	Prev Close	266.67
Shortable	Yes	LT Debt/Eq	0.32	Earnings	Apr 30 BMO	Payout	26.10%	Avg Volume	277.91K	Price	274.30
Recom	2.00	SMA20	4.45%	SMA50	5.08%	SMA200	25.41%	Volume	168,126	Change	2.86%

Jul-15-20

Downgrade

Stephens

Overweight → Equal-Weight

May-27-20

Downgrade

Stifel

Buy → Hold

$245 → $260

May-14-20

Initiated

The Benchmark Company

Buy

$290

Jan-08-20

Resumed

Stephens

Overweight

$250

Jan-08-20

Initiated

Wells Fargo

Equal Weight

$230

Jan-07-20

Initiated

Citigroup

Neutral

$235

Nov-15-19

Initiated

Stifel

Buy

Jul-02-19

Upgrade

Janney

Neutral → Buy

$200 → $270

Jan-14-19

Upgrade

Stephens

Equal-Weight → Overweight

Oct-31-18

Downgrade

Craig Hallum

Buy → Hold

Oct-17-18

Initiated

Goldman

Neutral

$190

Jun-15-18

Initiated

Argus

Buy

$185

Jul-13-17

Initiated

Wells Fargo

Market Perform

Feb-09-17

Initiated

Citigroup

Buy

$115

Jan-18-17

Initiated

Deutsche Bank

Buy

$115

Nov-10-16

Resumed

Leerink Partners

Outperform

$122

Jan-21-15

Reiterated

Robert W. Baird

Outperform

$102 → $104

Sep-20-13

Upgrade

Robert W. Baird

Neutral → Outperform

$76 → $90

Jun-08-12

Initiated

William Blair

Mkt Perform

Feb-01-12

Downgrade

Robert W. Baird

Outperform → Neutral

$81 → $71

Jul-13-20 10:09AM	Did Hedge Funds Make The Right Call On Bio-Techne Corporation (TECH) ? Insider Monkey
07:00AM	Bio-Techne To Host Conference Call On August 4, 2020 To Announce Fourth Quarter 2020 Financial Results PR Newswire
Jun-11-20 07:00AM	Bio-Techne And ZERO - The End Of Prostate Cancer Announce Partnership To Fund Education And Awareness Campaigns To Empower Men With Prostate Cancer PR Newswire -7.62%
Jun-09-20 02:09PM	Top Biotech Stocks for Q3 2020 Investopedia
07:00AM	Bio-Techne Continues to Expand Its Portfolio to Support SARS-CoV-2 and COVID-19 Research and Therapeutic Development PR Newswire
Jun-08-20 12:51PM	Hedge Funds Are Done Buying Bio-Techne Corporation (TECH)? Insider Monkey
07:00AM	Bio-Techne Announces Release of GMP ProDots Proteins to Support Cell and Gene Therapy Manufacturing Workflows PR Newswire
Jun-04-20 10:20AM	A 50-year technological revolution is about to begin. These are the stocks to own, says strategist MarketWatch
May-27-20 07:00AM	Bio-Techne To Present At The Jefferies Virtual Healthcare Conference PR Newswire
May-26-20 03:00AM	Leica Biosystems and Bio-Techne Announce European Launch of the CE-IVD RNAscope In Situ Hybridization Detection Kit PR Newswire
May-25-20 11:37AM	A Rising Share Price Has Us Looking Closely At Bio-Techne Corporation's (NASDAQ:TECH) P/E Ratio Simply Wall St.
May-20-20 08:12AM	The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test Benzinga
May-19-20 04:05PM	Bio-Techne And Kantaro Biosciences Announce Partnership To Develop And Scale Production Of COVID-19 Serology Test PR Newswire
May-18-20 06:00PM	Edited Transcript of TECH earnings conference call or presentation 30-Apr-20 1:00pm GMT Thomson Reuters StreetEvents
May-11-20 11:32AM	A Rising Share Price Has Us Looking Closely At Bio-Techne Corporation's (NASDAQ:TECH) P/E Ratio Simply Wall St.
May-07-20 10:35AM	Bio-Techne Announces Publication of ExoDx Prostate (IntelliScore) EPI Test Clinical Utility Study PR Newswire
May-04-20 01:26PM	Bio-Techne Corporation Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next Simply Wall St.
Apr-30-20 08:30PM	Bio-Techne Corp (TECH) Q3 2020 Earnings Call Transcript Motley Fool +6.54%
Apr-23-20 12:32PM	Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline Zacks
Apr-16-20 07:00AM	Bio-Techne Introduces RePlex Capabilities For Simple Western Assays On Jess PR Newswire +5.21%
Apr-15-20 07:00AM	Bio-Techne's Exosome Diagnostics Launches ExoDx Prostate At-Home Collection Kit PR Newswire
Apr-14-20 11:40AM	REGN vs. TECH: Which Stock Should Value Investors Buy Now? Zacks
Apr-09-20 11:12AM	Despite Its High P/E Ratio, Is Bio-Techne Corporation (NASDAQ:TECH) Still Undervalued? Simply Wall St.
Apr-08-20 07:00AM	Bio-Techne To Host Conference Call On April 30, 2020 To Announce Third Quarter 2020 Financial Results PR Newswire
Apr-01-20 04:01PM	Dr. Roeland Nusse: Gairdner Award Recipient and Bio-Techne Board of Directors Member PR Newswire
Mar-30-20 07:00AM	Extracellular Vesicles From Plasma Have Higher Tumor RNA Fraction Than Platelets PR Newswire
Mar-25-20 09:23AM	Bio-Techne's Ella On The Front Lines In Fight Against COVID-19 PR Newswire
Mar-23-20 12:26AM	Hedge Funds Have Never Been This Bullish On Bio-Techne Corporation (TECH) Insider Monkey
Mar-18-20 07:00AM	Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With General Services Administration PR Newswire
Feb-24-20 07:00AM	Bio-Techne To Present At The Cowen 40th Annual Health Care Conference PR Newswire
Feb-17-20 07:00AM	Bio-Techne To Present At The SVB Leerink 9th Annual Global Healthcare Conference PR Newswire
Feb-10-20 02:39AM	Edited Transcript of TECH earnings conference call or presentation 4-Feb-20 2:00pm GMT Thomson Reuters StreetEvents
Feb-06-20 02:14PM	Should You Take Comfort From Insider Transactions At Bio-Techne Corporation (NASDAQ:TECH)? Simply Wall St.
Feb-05-20 07:00AM	Bio-Techne Announces Availability Of Next Generation ELISA Kits PR Newswire
Feb-04-20 07:55AM	Techne (TECH) Lags Q2 Earnings and Revenue Estimates Zacks
07:00AM	Bio-Techne Corp. to Host Earnings Call ACCESSWIRE
06:30AM	Bio-Techne Releases Second Quarter Fiscal 2020 Results PR Newswire
06:30AM	Bio-Techne Declares Dividend PR Newswire
Jan-28-20 12:31PM	Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jan-21-20 08:30AM	Three Industry Leaders Form New Venture to Create Scalable Manufacturing Platforms for Cell and Gene Therapies Business Wire
Jan-09-20 07:00AM	Bio-Techne To Host Conference Call On February 4, 2020 To Announce Second Quarter 2020 Financial Results PR Newswire
Jan-07-20 07:00AM	Bio-Techne Rebrands Atlanta Biologicals Serum And Media As Part Of The R&D Systems Product Portfolio PR Newswire
Jan-02-20 07:00AM	Bio-Techne To Present At The 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-01-20 11:40AM	GILD vs. TECH: Which Stock Should Value Investors Buy Now? Zacks
Dec-23-19 01:10PM	Based On Its ROE, Is Bio-Techne Corporation (NASDAQ:TECH) A High Quality Stock? Simply Wall St.
Dec-21-19 07:21PM	Is Bio-Techne Corporation (TECH) A Good Stock To Buy? Insider Monkey
Dec-17-19 07:00AM	Bio-Techne's Exosome Diagnostics Lab Receives Accreditation From College of American Pathologists (CAP) PR Newswire
Nov-26-19 12:48PM	Premium Millennial Generation Portfolio Yahoo Finance
Nov-08-19 11:53AM	Is Bio-Techne Corporation's (NASDAQ:TECH) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-07-19 07:00AM	Bio-Techne To Present At The 2019 Stifel Healthcare Conference PR Newswire
Nov-06-19 09:30AM	CELG vs. TECH: Which Stock Is the Better Value Option? Zacks
07:00AM	Bio-Techne Licenses aTAG Technology from C4 Therapeutics, Inc. PR Newswire
Nov-05-19 07:00AM	Bio-Techne To Present At The Stephens Nashville Investment Conference PR Newswire
Oct-31-19 12:38AM	Edited Transcript of TECH earnings conference call or presentation 29-Oct-19 1:00pm GMT Thomson Reuters StreetEvents
Oct-29-19 07:55AM	Techne (TECH) Q1 Earnings Lag Estimates Zacks
07:32AM	The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga
06:30AM	Bio-Techne Releases First Quarter Fiscal 2020 Results PR Newswire
06:30AM	Bio-Techne Declares Dividend PR Newswire
Oct-28-19 03:42PM	Bio-Techne will open $40M+ facility in St. Paul American City Business Journals
07:00AM	Bio-Techne Announces Investment For New GMP Manufacturing Facility PR Newswire
Oct-14-19 08:10PM	Hedge Funds Have Never Been More Bullish On Bio-Techne Corporation (TECH) Insider Monkey
Oct-10-19 02:23PM	Medicare Issues Final Local Coverage Decision For Bio-Techne's ExoDx Prostate(IntelliScore) Test PR Newswire
Oct-08-19 09:15AM	Bio-Techne To Host Conference Call On October 29, 2019, To Announce First Quarter 2020 Financial Results PR Newswire
Oct-07-19 09:15AM	Bio-Techne Leverages The RNAscope Technology To Advance A Multiomic Approach To Antibody Validation PR Newswire
Oct-02-19 02:05PM	Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet? Simply Wall St.
Oct-01-19 03:50PM	5 Health Care Stocks Held By Gurus GuruFocus.com
Sep-26-19 03:38PM	Mairs and Power Growth Fund 2nd-Quarter Shareholder Letter GuruFocus.com
Sep-16-19 09:15AM	Bio-Techne Attains ISO 9001:2015 Certification for Fetal Bovine Serum Manufacturing Facility PR Newswire
Aug-28-19 05:48PM	Bio-Techne Corp (TECH) Files 10-K for the Fiscal Year Ended on June 30, 2019 GuruFocus.com
Aug-27-19 06:07AM	Bio-Techne (NASDAQ:TECH) Shareholders Booked A 99% Gain In The Last Five Years Simply Wall St.
Aug-23-19 07:16AM	5 Tips for Making Money in Penny Stocks InvestorPlace
Aug-20-19 09:15AM	Bio-Techne Introduces Maurice Empower® Control Kit For The Maurice System PR Newswire
Aug-15-19 09:15AM	Bio-Techne To Present At The Baird 2019 Global Healthcare Conference PR Newswire
08:22AM	New Strong Sell Stocks for August 15th Zacks
Aug-13-19 09:15AM	Bio-Techne And Cygnus Technologies Announce Partnership For 3G CHO-HCP Assay PR Newswire
Aug-10-19 02:50PM	Edited Transcript of TECH earnings conference call or presentation 6-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Aug-07-19 06:45AM	Should You Invest in the Invesco Dynamic Biotechnology &amp; Genome ETF (PBE)? Zacks
Aug-06-19 06:23PM	Bio-Techne Corp (TECH) Q4 2019 Earnings Call Transcript Motley Fool
08:55AM	Techne (TECH) Q4 Earnings and Revenues Lag Estimates Zacks
06:30AM	Bio-Techne Releases Fourth Quarter Fiscal 2019 Results PR Newswire
06:30AM	Bio-Techne Declares Dividend PR Newswire
Aug-05-19 01:36PM	Bio-Techne Corporation (NASDAQ:TECH): Earnings To Drop Next Year Simply Wall St.
Aug-02-19 11:46AM	Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2? Zacks
09:26AM	What's in Store for Cardinal Health (CAH) in Q4 Earnings? Zacks
Aug-01-19 11:55AM	Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store? Zacks
Jul-31-19 11:14AM	Can Patient Wins Aid GW Pharmaceuticals (GWPH) Q2 Earnings? Zacks
Jul-29-19 11:38AM	Can Bruker (BRKR) Q2 Earnings See BioSpin's Growth Revival? Zacks
Jul-25-19 07:33AM	Why Bio-Techne Corporation's (NASDAQ:TECH) High P/E Ratio Isn't Necessarily A Bad Thing Simply Wall St.
Jul-23-19 09:15AM	Uman Diagnostics And Bio-Techne Announce License And Supply Agreement For Neurofilament Light Assay PR Newswire
Jul-22-19 09:30AM	CBM or TECH: Which Is the Better Value Stock Right Now? Zacks
Jul-18-19 09:15AM	Bio-Techne To Host Conference Call On August 6, 2019, To Announce Fourth Quarter 2019 Financial Results PR Newswire
Jul-17-19 09:15AM	Bio-Techne Releases 32x8 Cartridge For The Ella Platform PR Newswire
Jul-16-19 07:01AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Jul-11-19 09:15AM	Bio-Techne Announces Commercial Release Of RNAscope® HiPlex Assay: A Multiplex In Situ Hybridization Assay For Tissues PR Newswire
Jul-09-19 10:10AM	Why the Earnings Surprise Streak Could Continue for Techne (TECH) Zacks
09:15AM	Bio-Techne CEO Chuck Kummeth Wins Entrepreneur Of The Year® 2019 Award In The Heartland PR Newswire
Jul-02-19 03:40PM	Baron Capital Commentary: Early Detection for the Win GuruFocus.com
01:53PM	At US$209, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely? Simply Wall St.
Jun-26-19 09:07AM	Bio-Techne China Recognized With "Decade of Contribution Award" PR Newswire
Jun-25-19 04:05PM	Bio-Techne Appoints Rupert Vessey to Board of Directors PR Newswire

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. Bio-Techne Corporation has partnership with Kantaro Biosciences to develop and scale production of COVID-19 serology test. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Furlow Brenda S.	SVP - General Counsel	Jul 09	Option Exercise	108.49	9,079	984,981	13,390	Jul 13 04:02 PM
Furlow Brenda S.	SVP - General Counsel	Jul 09	Sale	275.76	9,079	2,503,652	4,311	Jul 13 04:02 PM
Hippel James	Chief Financial Officer	Jul 07	Option Exercise	108.49	2,577	279,579	11,884	Jul 08 05:47 PM
Hippel James	Chief Financial Officer	Jul 07	Sale	271.43	2,577	699,482	9,307	Jul 08 05:47 PM
Hippel James	Chief Financial Officer	Jul 06	Option Exercise	108.49	21,502	2,332,752	30,809	Jul 08 05:47 PM
Hippel James	Chief Financial Officer	Jul 06	Sale	271.61	21,502	5,840,152	9,307	Jul 08 05:47 PM
Eansor Norman David	President-Protein Sciences	May 29	Option Exercise	108.49	7,909	858,047	7,909	Jun 01 05:58 PM
WIENS HAROLD J	Director	May 29	Option Exercise	101.19	3,985	403,242	8,828	Jun 02 05:13 PM
WIENS HAROLD J	Director	May 29	Sale	260.00	3,985	1,036,100	4,843	Jun 02 05:13 PM
Eansor Norman David	President-Protein Sciences	May 29	Sale	262.00	7,909	2,072,140	0	Jun 01 05:58 PM
Furlow Brenda S.	SVP - General Counsel	May 28	Option Exercise	105.51	7,595	801,358	10,306	Jun 01 05:58 PM
Eansor Norman David	President-Protein Sciences	May 28	Option Exercise	108.49	3,448	374,074	3,448	Jun 01 05:58 PM
Eansor Norman David	President-Protein Sciences	May 28	Sale	260.19	3,448	897,134	0	Jun 01 05:58 PM
Furlow Brenda S.	SVP - General Counsel	May 28	Sale	260.14	5,995	1,559,533	4,311	Jun 01 05:58 PM
Kummeth Charles R.	Chief Executive Officer	May 26	Option Exercise	86.25	21,159	1,824,964	151,148	May 28 05:41 PM
Eansor Norman David	President-Protein Sciences	May 22	Option Exercise	104.04	12,600	1,310,937	12,600	May 26 05:13 PM
Eansor Norman David	President-Protein Sciences	May 22	Sale	267.93	12,600	3,375,926	0	May 26 05:13 PM
Eansor Norman David	President-Protein Sciences	May 21	Option Exercise	94.35	11,037	1,041,341	11,037	May 26 05:13 PM
BAUMGARTNER ROBERT V	Director	May 21	Option Exercise	70.35	5,000	351,750	14,221	May 26 05:13 PM
BAUMGARTNER ROBERT V	Director	May 21	Sale	266.42	5,000	1,332,117	9,221	May 26 05:13 PM
Eansor Norman David	President-Protein Sciences	May 21	Sale	267.49	11,037	2,952,316	0	May 26 05:13 PM
WIENS HAROLD J	Director	May 06	Option Exercise	87.34	4,260	372,068	9,481	May 08 04:17 PM
WIENS HAROLD J	Director	May 06	Sale	250.00	4,260	1,065,000	5,221	May 08 04:17 PM
WIENS HAROLD J	Director	Apr 30	Option Exercise	91.78	4,000	367,120	9,221	May 04 04:35 PM
WIENS HAROLD J	Director	Apr 30	Sale	225.00	4,000	900,000	5,221	May 04 04:35 PM
Eansor Norman David	President-Protein Sciences	Mar 04	Sale	198.68	1,387	275,569	0	Mar 06 04:08 PM
HIGGINS JOHN L	Director	Feb 12	Option Exercise	61.46	5,000	307,300	9,021	Feb 14 04:13 PM
HIGGINS JOHN L	Director	Feb 12	Sale	205.23	5,000	1,026,133	4,021	Feb 14 04:13 PM
Kummeth Charles R.	Chief Executive Officer	Jan 06	Option Exercise	67.46	10,276	693,219	140,265	Jan 08 04:34 PM
Kummeth Charles R.	Chief Executive Officer	Jan 06	Sale	217.28	10,276	2,232,769	129,989	Jan 08 04:34 PM
Kummeth Charles R.	Chief Executive Officer	Jan 03	Option Exercise	67.46	7,999	539,613	137,988	Jan 06 04:39 PM
Kummeth Charles R.	Chief Executive Officer	Jan 03	Sale	217.56	7,999	1,740,240	129,989	Jan 06 04:39 PM
Kummeth Charles R.	Chief Executive Officer	Jan 02	Option Exercise	67.46	19,843	1,338,609	149,832	Jan 06 04:39 PM
Kummeth Charles R.	Chief Executive Officer	Jan 02	Sale	218.59	19,843	4,337,541	129,989	Jan 06 04:39 PM
Kummeth Charles R.	Chief Executive Officer	Dec 24	Option Exercise	67.46	471	31,774	130,460	Dec 27 04:31 PM
Kummeth Charles R.	Chief Executive Officer	Dec 24	Sale	222.18	471	104,648	129,989	Dec 27 04:31 PM
Kummeth Charles R.	Chief Executive Officer	Dec 23	Option Exercise	67.46	659	44,456	130,648	Dec 27 04:31 PM
Kummeth Charles R.	Chief Executive Officer	Dec 23	Sale	222.08	659	146,351	129,989	Dec 27 04:31 PM
Kummeth Charles R.	Chief Executive Officer	Dec 20	Option Exercise	67.46	5,767	389,042	135,756	Dec 23 04:31 PM
Kummeth Charles R.	Chief Executive Officer	Dec 20	Option Exercise	67.46	5,767	389,042	135,756	Dec 23 04:32 PM
Kummeth Charles R.	Chief Executive Officer	Dec 20	Sale	222.06	5,767	1,280,632	129,989	Dec 23 04:32 PM
Kummeth Charles R.	Chief Executive Officer	Dec 20	Sale	222.06	5,767	1,280,632	129,989	Dec 23 04:31 PM
Furlow Brenda S.	SVP - General Counsel	Dec 12	Option Exercise	94.35	8,000	754,800	10,711	Dec 17 04:32 PM
Furlow Brenda S.	SVP - General Counsel	Dec 12	Sale	215.60	8,000	1,724,772	2,711	Dec 17 04:32 PM
Kummeth Charles R.	Chief Executive Officer	Dec 10	Option Exercise	67.46	703	47,424	136,459	Dec 12 04:35 PM
Kummeth Charles R.	Chief Executive Officer	Dec 10	Sale	222.01	703	156,073	135,756	Dec 12 04:35 PM
WIENS HAROLD J	Director	Dec 04	Option Exercise	87.83	2,000	175,660	7,221	Dec 06 04:50 PM
WIENS HAROLD J	Director	Dec 04	Sale	217.85	2,000	435,693	5,221	Dec 06 04:50 PM
Kummeth Charles R.	Chief Executive Officer	Nov 29	Sale	222.62	100	22,262	135,756	Dec 02 04:22 PM
Kummeth Charles R.	Chief Executive Officer	Nov 27	Option Exercise	67.46	11,772	794,139	147,628	Dec 02 04:22 PM
Kummeth Charles R.	Chief Executive Officer	Nov 27	Sale	222.12	11,772	2,614,814	135,856	Dec 02 04:22 PM
Nusse Roeland	Director	Nov 25	Option Exercise	60.79	15,000	911,900	20,721	Nov 29 11:35 AM
Nusse Roeland	Director	Nov 25	Sale	219.33	8,347	1,830,731	12,374	Nov 29 11:35 AM
Hippel James	Chief Financial Officer	Nov 22	Option Exercise	94.35	23,651	2,231,472	32,958	Nov 25 04:25 PM
Hippel James	Chief Financial Officer	Nov 22	Sale	215.59	23,651	5,098,901	9,307	Nov 25 04:25 PM
Hippel James	Chief Financial Officer	Nov 21	Option Exercise	94.35	11,349	1,070,778	20,656	Nov 25 04:25 PM
Hippel James	Chief Financial Officer	Nov 21	Sale	215.36	11,349	2,444,132	9,307	Nov 25 04:25 PM
Kummeth Charles R.	Chief Executive Officer	Sep 09	Buy	185.00	200	37,000	100	Sep 11 04:42 PM
Kummeth Charles R.	Chief Executive Officer	Aug 13	Option Exercise	67.46	7,410	499,879	110,877	Aug 15 04:45 PM
BAUMGARTNER ROBERT V	Director	Aug 07	Buy	191.06	500	95,530	8,726	Aug 09 04:12 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience